Dr. Aron Blaesi, inventor of expandable, gastroretentive fibrous dosage forms presenting dosage forms before and after expansion due to water absorption. (Photo: Business Wire)
Schematics of the passage of dosage forms through the gastrointestinal tract, and drug concentration in blood after repeated dosing: (a) and (b) particulate dosage form, and (c) and (d) gastroretentive fibrous dosage form. cd,b: drug concentration in blood; t: time; td: dosing interval. The schematics are adapted from A.H. Blaesi and N. Saka, Int. J. Pharm. (2024) 124360 (in press) https://doi.org/10.1016/j.ijpharm.2024.124360. (Graphic: Business Wire)
Fluoroscopic images of the abdomen of a dog at various times after administering an Enzian dosage form. Initially, the dosage form was unimpaired in the stomach. Then it expanded due to gastric fluid absorption and formed a viscoelastic gel that resided in the stomach for prolonged time. By 45 hours the dosage form was fragmented in the intestine. By 48 hours it was entirely dissolved. The animal experiments were conducted at the Diagnostic Imaging Research Unit (DIRU), University of Zurich, led by Dr. Henning Richter. The images are adapted from A.H. Blaesi et al. Int. J. Pharm. (2022) 120792 https://doi.org/10.1016/j.ijpharm.2021.120792. The work received financial support from the innovation agency of the government of Switzerland (Innosuisse). (Photo: Business Wire)
Scanning electron micrograph of the microstructure of a fibrous dosage form. The dosage form comprises a 3D-printed cross-ply structure of water-absorbing, cellulose fibers. The image is adapted from A.H. Blaesi et al. Int. J. Pharm. (2023) 122378 https://doi.org/10.1016/j.ijpharm.2022.122378. (Photo: Business Wire)
